Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination.

Lee JY, Kim MJ, Thomas S, Oorschot V, Ramm G, Aui PM, Sekine Y, Deliyanti D, Wilkinson-Berka J, Niego B, Harvey AR, Theotokis P, McLean C, Strittmatter SM, Petratos S.

J Neurosci. 2019 Jul 10;39(28):5562-5580. doi: 10.1523/JNEUROSCI.1760-18.2019. Epub 2019 May 6.

PMID:
31061088
2.

t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke.

Draxler DF, Lee F, Ho H, Keragala CB, Medcalf RL, Niego B.

Front Immunol. 2019 Mar 27;10:591. doi: 10.3389/fimmu.2019.00591. eCollection 2019.

3.
4.

Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin.

Niego B, Lee N, Larsson P, De Silva TM, Au AE, McCutcheon F, Medcalf RL.

PLoS One. 2017 May 16;12(5):e0177332. doi: 10.1371/journal.pone.0177332. eCollection 2017.

5.

Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.

Bonnard T, Tennant Z, Niego B, Kanojia R, Alt K, Jagdale S, Law LS, Rigby S, Medcalf RL, Peter K, Hagemeyer CE.

J Am Heart Assoc. 2017 Feb 3;6(2). pii: e004535. doi: 10.1161/JAHA.116.004535.

6.

Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse.

Larsson P, Alwis I, Niego B, Sashindranath M, Fogelstrand P, Wu MC, Glise L, Magnusson M, Daglas M, Bergh N, Jackson SP, Medcalf RL, Jern S.

J Thromb Haemost. 2016 Dec;14(12):2496-2508. doi: 10.1111/jth.13527. Epub 2016 Nov 23.

7.

The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.

Dahl LC, Nasa Z, Chung J, Niego B, Tarlac V, Ho H, Galle A, Petratos S, Lee JY, Alderuccio F, Medcalf RL.

PLoS One. 2016 Jul 18;11(7):e0158653. doi: 10.1371/journal.pone.0158653. eCollection 2016.

8.

Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Niego B, Medcalf RL.

J Cereb Blood Flow Metab. 2014 Aug;34(8):1283-96. doi: 10.1038/jcbfm.2014.99. Epub 2014 Jun 4. Review.

9.

t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.

Freeman R, Niego B, Croucher DR, Pedersen LO, Medcalf RL.

Brain Res. 2014 May 27;1565:63-73. doi: 10.1016/j.brainres.2014.03.027. Epub 2014 Mar 25.

PMID:
24675027
10.

Improved method for the preparation of a human cell-based, contact model of the blood-brain barrier.

Niego B, Medcalf RL.

J Vis Exp. 2013 Nov 12;(81):e50934. doi: 10.3791/50934.

11.

t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.

Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL.

Blood. 2012 May 17;119(20):4752-61. doi: 10.1182/blood-2011-07-369512. Epub 2012 Jan 19.

12.

Thrombin-induced activation of astrocytes in mixed rat hippocampal cultures is inhibited by soluble thrombomodulin.

Niego B, Samson AL, Petersen KU, Medcalf RL.

Brain Res. 2011 Mar 24;1381:38-51. doi: 10.1016/j.brainres.2011.01.016. Epub 2011 Jan 15.

PMID:
21241677
13.

A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.

Samson AL, Borg RJ, Niego B, Wong CH, Crack PJ, Yongqing T, Medcalf RL.

Blood. 2009 Aug 27;114(9):1937-46. doi: 10.1182/blood-2009-02-203448. Epub 2009 Jul 7.

14.

Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.

Samson AL, Nevin ST, Croucher D, Niego B, Daniel PB, Weiss TW, Moreno E, Monard D, Lawrence DA, Medcalf RL.

J Neurochem. 2008 Nov;107(4):1091-101. doi: 10.1111/j.1471-4159.2008.05687.x. Epub 2008 Sep 15.

15.

Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid.

Niego B, Horvath A, Coughlin PB, Pugsley MK, Medcalf RL.

Blood Coagul Fibrinolysis. 2008 Jun;19(4):322-4. doi: 10.1097/MBC.0b013e3282f54568. No abstract available.

PMID:
18469556
16.

Two conserved regions within the tissue-type plasminogen activator gene promoter mediate regulation by brain-derived neurotrophic factor.

Daniel PB, Lux W, Samson AL, Schleuning WD, Niego B, Weiss TW, Tjärnlund-Wolf A, Medcalf RL.

FEBS J. 2007 May;274(9):2411-23. Epub 2007 Apr 5.

17.

Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo.

Weiss TW, Samson AL, Niego B, Daniel PB, Medcalf RL.

FASEB J. 2006 Nov;20(13):2369-71. Epub 2006 Oct 5.

PMID:
17023520
18.

Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy.

Plotnikov A, Niego B, Ophir R, Korenstein R, Keisari Y.

Prostate. 2006 Nov 1;66(15):1620-30.

PMID:
16941466

Supplemental Content

Support Center